The Gordon and Jessie Gilmour Leukaemia Research Laboratory is researching myeloid blood cancers that include myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN) as part its translational leukaemia research work. These are very aggressive and rapidly fatal blood cancers that are among the most common types of cancer affecting Australians.
The laboratory’s efforts concentrate on understanding how leukaemia stem cells in AML and MPN are able to regenerate leukaemia (or cause relapse in patients), even after cytotoxic chemotherapy. Research has focused on generating robust models of leukaemia and dissecting the pathways of self-renewal in leukaemia stem cells and normal blood stem cells.
Lab head, Associate Professor Steven Lane, is the CSL Centenary Fellow for 2017. This support will allow him to begin tailoring treatments to individual patients, identify new drug pathways and explore repurposing existing drugs to target resistant leukaemia types.
Associate Professor Steven Lane’s complete list of publications can be viewed at his Google Scholar page.
- Myeloproliferative neoplasms
- Characterising biomarkers of resistance and response to standard and novel therapies in Acute Myeloid Leukaemia
- What determines leukaemic stem cell maintenance and resistance to chemotherapy?
- Role of MYC in leukaemic cell differentiation
- CRISPR-Cas9 approaches to model blood cancers in vivo
If you wish to apply for QIMR Berghofer's student program,
click here for more information.